Nexalin Technology (NXL) Other Non-Current Assets (2024)
Nexalin Technology's (NXL) quarterly Other Non-Current Assets came in at $864.0 in Q4 2024, down 98.41% quarter-over-quarter from $54414.0 in Q2 2024.
Nexalin Technology (NXL) Other Non-Current Assets (2024) Analysis & Trends
Nexalin Technology's Other Non-Current Assets history runs 1 years deep, the most recent figure standing at $864.0 for Q4 2024.
- On a quarterly basis, Other Non-Current Assets changed N/A year-over-year to $864.0 in Q4 2024; TTM through Dec 2024 was $864.0, a N/A change from a year earlier, with the FY2024 full-year figure at $864.0, changed N/A from the prior year.
- Other Non-Current Assets slipped to $864.0 in Q4 2024 per NXL's latest filing, from $54414.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $54414.0 in Q2 2024 and bottomed at $864.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 3.17 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 4.15 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 2.05 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 738.90 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 285.90 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 828.89 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 2.25 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 164.00 Mn |
| 10 | Nexalin Technology | 9.32 Mn | 6.61 Mn | 13,133.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 864.00 |
| Jun 30, 2024 | 54,414.00 |